Source comparison
TB-500 Absorption Mechanics in Fasted vs Fed States
Subcutaneous TB-500 administration initiates a multi-step absorption process: peptide depot formation at injection site → lymphatic uptake → entry into systemic circulation → tissue distribution governed by blood flow and receptor availability. Each step is in
This comparison does not assign a generated winner or score.
- Subcutaneous TB-500 administration initiates a multi-step absorption process: peptide depot formation at injection site → lymphatic uptake → entry into systemic circulation → tissue distribution governed by blood flow and receptor availability. Each step is influenced by metabolic state. In fasted conditions, subcutaneous blood flow remains elevated due to sympathetic tone, accelerating depot clearance. Gastric pH stabilizes between 1.5–2.5 without food buffering, which matters because any peptide that reaches the stomach (through lymphatic drainage or accidental oral exposure) degrades rapidly above pH 3.0.
- Insulin is the primary confounding variable. Postprandial insulin elevation. Peaking 30–90 minutes after carbohydrate intake. Triggers widespread receptor internalization as cells shift from catabolic to anabolic signaling. TB-500's mechanism requires binding to cell surface receptors before internalization occurs. Research published in the Journal of Peptide Science demonstrated that insulin pre-treatment reduced TB-500 cellular uptake by 38% in vitro, likely through competitive receptor occupancy and altered membrane fluidity. The clinical implication: dosing TB-500 within two hours of a meal means a significant fraction of the injected peptide never reaches target tissues at therapeutic concentration.
- Gastric emptying rate also matters for any peptide with potential oral absorption or lymphatic recirculation. In fasted state, gastric emptying half-time is approximately 60–90 minutes for liquids. After a mixed meal, this extends to 3–4 hours. Slower gastric transit increases exposure time to pepsin and low pH, both of which degrade unprotected peptides. While subcutaneous TB-500 bypasses first-pass gastric degradation, lymphatic circulation does route a small percentage through the gut-associated lymphoid tissue (GALT), where fed-state inflammatory signaling from digestion can alter peptide stability. The magnitude of this effect is small. Likely under 5% of total dose. But it compounds with insulin interference to reduce overall bioavailability.